Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics advancing targeted delivery of siRNA therapeutics, today announced a €16 million ($18 million) Seed financing round to expand DELiveri, its…
Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver
What they do:
Deliver genes to any cell with AI
Quick facts:
HQ: London, United Kingdom
What they do:
Artificial intelligence for drug discovery.
Quick facts:
HQ: San Francisco, CA, United States
Funding:
$19.8M · Equity · Mar 2026
What they do:
Unleash the potential of genomic medicine using AI
Quick facts:
Funding:
€23.2M · Series B · Oct 2026
What they do:
Medicinal Chemistry powered by Machine Learning
Quick facts:
HQ: Boston, MA, United States
What they do:
We're building fully automated labs for protein engineering
Quick facts:
HQ: Lausanne, Switzerland
What they do:
Using the immune system to cure disease
Quick facts:
HQ: San Francisco, CA, United States
Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics advancing targeted delivery of siRNA therapeutics, today announced a €16 million ($18 million) Seed financing round to expand DELiveri, its…
United Kingdom
Latest round: €16M Seed (Oct 2026).
Similar startups: Nanograb, Numerion Labs, and WhiteLab Genomics.